| Literature DB >> 26271067 |
Gilles Montalescot1, David Brieger2, Anthony J Dalby3, Seung-Jung Park4, Roxana Mehran5.
Abstract
The duration of dual antiplatelet therapy (DAPT) after coronary stenting has been evaluated in randomized studies with apparently conflicting results. Although longer exposure associates with more bleeding complications, late stent thrombosis (ST) and myocardial infarction are reduced. In addition, as new drug-eluting stents carry a lower risk of ST compared with the first-generation drug-eluting stents and possibly even bare-metal stents, a shift toward better protection from ST may have an effect on the duration and intensity of DAPT. Whether the duration of DAPT should be shorter or longer than the currently recommended 6 to 12 months is analyzed in this review, drawing on lessons from the most recent studies.Entities:
Keywords: P2Y(12) inhibitors; antiplatelet therapy; aspirin; coronary stent; drug-eluting stent
Mesh:
Substances:
Year: 2015 PMID: 26271067 DOI: 10.1016/j.jacc.2015.05.053
Source DB: PubMed Journal: J Am Coll Cardiol ISSN: 0735-1097 Impact factor: 24.094